© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Voyager Therapeutics, Inc. (VYGR) stock surged +2.20%, trading at $5.34 on NASDAQ, up from the previous close of $5.22. The stock opened at $5.23, fluctuating between $5.14 and $5.35 in the recent session.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Employees | 162 |
Beta | 0.89 |
Sales or Revenue | $250.01M |
5Y Sales Change% | 23.458% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Voyager Therapeutics, Inc. (NASDAQ: VYGR) stock price is $5.34 in the last trading session. During the trading session, VYGR stock reached the peak price of $5.35 while $5.14 was the lowest point it dropped to. The percentage change in VYGR stock occurred in the recent session was 2.2% while the dollar amount for the price change in VYGR stock was $0.12.
The NASDAQ listed VYGR is part of Biotechnology industry that operates in the broader Healthcare sector. Voyager Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Todd Carter Ph.D.
Chief Science Officer
Dr. Mark A. Kay M.D., Ph.D.
Founder
Mr. Peter P. Pfreundschuh CPA
Chief Financial Officer
Dr. Phillip D. Zamore
Founder
Mr. Robert W. Hesslein
Senior Vice President & Gen. Counsel
Mr. G. Andre Turenne
Advisor
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Pres, Chief Executive Officer & Director
Dr. Phillip D. Zamore Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Krystof Bankiewicz M.D., Ph.D.
Founder
Ms. Robin Swartz
Chief Operating Officer
Ms. Michelle Quinn Smith
Chief HR Officer
Mr. Robert W. Hesslein Esq., J.D.
Senior Vice President & Gen. Counsel
Ms. Jacquelyn Fahey Sandell Esq., J.D.
Chief Legal Officer
VYGR's closing price is 4.61% higher than its 52-week low of $4.99 where as its distance from 52-week high of $10.66 is -51.03%.
Number of VYGR employees currently stands at 162.
Official Website of VYGR is: https://www.voyagertherapeutics.com
VYGR could be contacted at phone 857 259 5340 and can also be accessed through its website. VYGR operates from 75 Sidney Street, Cambridge, MA 02139, United States.
VYGR stock volume for the day was 138.59K shares. The average number of VYGR shares traded daily for last 3 months was 488.8K.
The market value of VYGR currently stands at $291.43M with its latest stock price at $5.34 and 54.63M of its shares outstanding.